


FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10



Tumour Volume (mm3)
3000
2000
1000
0
Vehicle
MEN1611 6.5 mg/Kg
Benacizumab 2 mg/Kg
Combo
0
10
20
30
Days after implantation

FIGURE 11




FIGURE 12




FIGURE 13



3000
2000
1000
0
-1000
Tumour Volume (mm3)
Vehicle
MEN1611 6.5 mg/Kg
Erlotinib 50 mg/Kg
Combo
10
20
30
40
Days after implantation

FIGURE 14

N°	Fulvestrant (µM)	MEN1611 (µM)	CI
1	0.0049	0.013	0.139
2	0.0049	0.068	0.053
3	0.0049	0.34	0.142
4	0.0049	1.7	0.193
5	0.0049	8.5	1.274
6	0.024	0.013	0.324
7	0.024	0.068	0.242
8	0.024	0.34	0.214
9	0.024	1.7	0.865
10	0.024	8.5	0.627
11	0.124	0.013	0.318
12	0.124	0.068	0.343
13	0.124	0.34	0.288
14	0.124	1.7	0.247
15	0.124	8.5	0.761
16	0.62	0.013	0.489
17	0.62	0.068	0.391
18	0.62	0.34	0.468
19	0.62	1.7	0.532
20	0.62	8.5	0.746

FIGURE 15



2500
2000
1500
1000
500
0
Tumor Volume (mm3)
Vehicle
MEN1611 6.5 mg/Kg
Erlotinib 25 mg/Kg
Combo
0
10
20
30
40
Days post implant

FIGURE 16



500
400
300
200
100
0
Tumor volume (mm³)
7
14
21
28
35
42
Days after tumor implantation
CTRL
GEF
MEN1611
Combination

FIGURE 17